telitacicept

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
telitacicept

GtoPdb Ligand ID: 11827

Synonyms: RC-18 | RC18 | Tai'ai®

telitacicept is an approved drug (China (2021))

Compound class: Peptide

Comment: Telitacicept (RC18) is a recombinant fusion protein that combines the ligand-binding domain of the TACI receptor and the Fc component of human IgG. It was designed to inhibit the signalling of B cell BAFF (a.k.a. BLyS; TNFSF13B) and APRIL (TNFSF13) as a disease-modifying mechainism for the treatment of B cell-mediated autoimmune diseases [2-4,6].

Immunopharmacology Comments
Telitacicept is approved in China as a treatment for active SLE. It inhibits activity of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand).

Immunopharmacology Comments

Telitacicept is approved in China as a treatment for active SLE. It inhibits activity of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand).

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Systemic lupus erythematosus	Disease Ontology: DOID:9074 OMIM: 152700 Orphanet: ORPHA536	Approved therapy for SLE (China)
Myasthenia gravis	Disease Ontology: DOID:437 OMIM: 254200 Orphanet: ORPHA589	Approved drug for MG (China)
Rheumatoid arthritis	Disease Ontology: DOID:7148 OMIM: 180300	Approved drug for RA (China)